- Trials with a EudraCT protocol (46)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
46 result(s) found for: DNA binding.
Displaying page 1 of 3.
EudraCT Number: 2020-005888-31 | Sponsor Protocol Number: EHVA_P01/ANRS_VRI08 | Start Date*: 2022-10-20 | |||||||||||
Sponsor Name:Inserm-ANRS | |||||||||||||
Full Title: A phase I, prophylactic HIV vaccine trial to evaluate the safety and immunogenicity of HIV Clade C DREP alone and in Combination with a Clade C ENV protein in healthy HIV-uninfected adults. | |||||||||||||
Medical condition: it's a Phase 1-2 preventive , prophilactic HIV vaccine trial. Vaccine target are healthy subjects aged from 18 to 55 years old. Safety and the immunogenicity of DREP-HIV-PT1 vaccine will be evaluat... | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-000476-26 | Sponsor Protocol Number: N14DAR | Start Date*: 2020-07-13 | ||||||||||||||||||||||||||||||||||||||||||||||
Sponsor Name:Netherlands Cancer Institute | ||||||||||||||||||||||||||||||||||||||||||||||||
Full Title: Dynamics of Androgen Receptor genomics and transcriptomics after neoadjuvant androgen ablation (DARANA) | ||||||||||||||||||||||||||||||||||||||||||||||||
Medical condition: Prostate cancer | ||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male | |||||||||||||||||||||||||||||||||||||||||||||||
Trial protocol: NL (Ongoing) | ||||||||||||||||||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-003280-38 | Sponsor Protocol Number: PSY-NIL-0006 | Start Date*: 2016-05-04 | |||||||||||
Sponsor Name:Medical University of Vienna | |||||||||||||
Full Title: Positron Emission Tomography assessment of Ketamine Binding of the Serotonin Transporter and its Relevance for Rapid Antidepressant Response | |||||||||||||
Medical condition: 20 patients with severe unipolar depression (structured clinical interview for DSM-IV and the 17-item Hamilton Depression Rating Scale), also 20 age and sex matched healthy controls. plus 12 HC f... | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-023430-23 | Sponsor Protocol Number: EMR701048_009 | Start Date*: 2011-01-17 | |||||||||||
Sponsor Name:Merck Serono S.A. | |||||||||||||
Full Title: A phase IIIb, open-label, single-arm, multicenter study to assess the immunogenicity of the r-hGH liquid multidose formulation (Saizen solution for injection) when administered to male and female a... | |||||||||||||
Medical condition: This is GH replacement therapy in adult subjects with documented Growth Hormone Deficiency (GHD) either idiopathic or acquired and childhood- or adult-onset | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) CZ (Completed) GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-004902-13 | Sponsor Protocol Number: D0490C00023 | Start Date*: 2015-04-09 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: A 12-Week, Multicenter, Randomized, Parallel-Group Study to Assess the Safety, Tolerability, Pharmacokinetics, Biomarker Effects, Efficacy, and Effect on Microglia Activation, as Measured by Positr... | |||||||||||||
Medical condition: Multiple system atrophy (MSA) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) FI (Completed) SE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-019374-32 | Sponsor Protocol Number: CP-4-003 | Start Date*: 2010-07-15 | |||||||||||
Sponsor Name:ModigeneTech Ltd. | |||||||||||||
Full Title: A Phase II, Dose and Frequency Finding Study of MOD-4023 in Growth Hormone Deficient Adults (GHDA) | |||||||||||||
Medical condition: Growth Hormone Deficiency | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: SK (Completed) HU (Completed) SI (Completed) CZ (Completed) DE (Completed) AT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-002248-42 | Sponsor Protocol Number: JMC-2014-6TG/6MP | Start Date*: 2014-10-22 |
Sponsor Name:Bonkolab, Rigshospitalet | ||
Full Title: The TEAM Study (Thiopurine EnhAnced Maintenance therapy) A Phase 1-2 Study of 6-Thioguanine in Combination with Methotrexate and 6-Mercaptopurine During Maintenance Therapy of Childhood, Adolesce... | ||
Medical condition: Acute Lymphoblastic Leukemia Lymphoblastic Non-Hodgkin’s Lymphoma | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: DK (Completed) FI (Completed) | ||
Trial results: View results |
EudraCT Number: 2021-005604-35 | Sponsor Protocol Number: APEC1621B | Start Date*: 2022-01-18 | |||||||||||
Sponsor Name:National Cancer Institute (NCI) | |||||||||||||
Full Title: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of JNJ-42756493 (Erdafitinib) in Patients With Tumors Harboring FGFR1/2/3/4 Alterations | |||||||||||||
Medical condition: Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-000212-34 | Sponsor Protocol Number: AG348-C-018 | Start Date*: 2021-10-11 | |||||||||||
Sponsor Name:Agios Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Phase 3, Double-blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Mitapivat in Subjects With Transfusion-Dependent Alpha- or Beta-Thalassemia (ENERGIZ... | |||||||||||||
Medical condition: Transfusion-Dependent Alpha- or Beta-Thalassemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) DK (Trial now transitioned) IT (Trial now transitioned) BG (Trial now transitioned) FR (Trial now transitioned) NL (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-000785-37 | Sponsor Protocol Number: GS-US-320-1092 | Start Date*: 2016-08-26 | |||||||||||
Sponsor Name:Gilead Sciences, Inc. | |||||||||||||
Full Title: A Randomized, Double-Blind Evaluation of the Pharmacokinetics, Safety, and Antiviral Efficacy of Tenofovir Alafenamide (TAF) in Adolescents with Chronic Hepatitis B Virus Infection | |||||||||||||
Medical condition: Chronic Hepatitis B | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA BE (Completed) IT (Prematurely Ended) RO (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-002534-23 | Sponsor Protocol Number: 3124001 | Start Date*: 2018-02-08 | |||||||||||
Sponsor Name:Orion Corporation Orion Pharma | |||||||||||||
Full Title: SAFETY AND PHARMACOKINETICS OF ODM-208 IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER | |||||||||||||
Medical condition: Metastatic castration-resistant prostate cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: FI (Trial now transitioned) FR (Ongoing) GB (Temporarily Halted) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-005305-19 | Sponsor Protocol Number: D5130C00030 | Start Date*: 2008-11-17 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: A Randomised, Double-Blind, Outpatient, Crossover Study of the Anti-platelet Effects of AZD6140 Compared with Clopidogrel in Patients with Stable Coronary Artery Disease Previuosly Identified as Cl... | |||||||||||||
Medical condition: Stable Coronary Artery Disease AZD6140 is under development for the prevention of thrombotic events in patients with non-ST and ST elevation coronary syndromes | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-002204-33 | Sponsor Protocol Number: C32322 | Start Date*: 2007-03-02 | |||||||||||
Sponsor Name:UCB Pharma S.A. | |||||||||||||
Full Title: Double-blind, placebo-controlled, randomized, parallel-group Phase II study in subjects with relapsing forms of multiple sclerosis (MS) to evaluate the safety, tolerability, and effects of two dose... | |||||||||||||
Medical condition: Relapsing forms of multiple slerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) DE (Completed) FI (Prematurely Ended) HU (Completed) SE (Prematurely Ended) GB (Completed) ES (Completed) FR (Completed) NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-002843-81 | Sponsor Protocol Number: 057 | Start Date*: 2020-01-07 |
Sponsor Name:IMEA | ||
Full Title: Switch to Tenofovir Alafenamide (TAF), Emtricitabine (FTC), Bictegravir (BIC)(Biktarvy®) in HIV-1-infected patients over 65 years old at risk of polymedication | ||
Medical condition: HIV-1-infected patient Age > 65 years old Plasma HIV RNA ≤ 50 copies/mL for ≥ 6 months: one blip between 50 et 200 cp/ml is allowed in the last 6 months before screening. Currently receiving an ant... | ||
Disease: | ||
Population Age: Elderly | Gender: Male, Female | |
Trial protocol: FR (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2017-000099-27 | Sponsor Protocol Number: HEAT01 | Start Date*: 2017-04-26 | |||||||||||
Sponsor Name:The Department of Urology | |||||||||||||
Full Title: Toxicity of first-line abiraterone versus enzalutamide in men with metastatic castration-resistant prostate cancer: A randomized clinical trial | |||||||||||||
Medical condition: Metastisc castration resistant prostate cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-004241-32 | Sponsor Protocol Number: EDOLAS | Start Date*: 2020-02-07 | |||||||||||
Sponsor Name:SOCIETA' ITALIANA MALATTIE INFETTIVE E TROPICALI | |||||||||||||
Full Title: Efficacy and safety of early switching to dolutegravir/lamivudine (DTG/3TC) from INSTI-based three-drug regimens in HIV-1-infected adults previously naïve who achieve virological suppression | |||||||||||||
Medical condition: HIV-1 infected individuals currently taking an INSTI-based three-drug first-line regimen for less than 18 months and who have been virologically suppressed with HIV-1 RNA <50 copies/mL | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-019183-36 | Sponsor Protocol Number: CFD4870g | Start Date*: 2011-06-16 | |||||||||||
Sponsor Name:GENENTECH, Inc. | |||||||||||||
Full Title: A PHASE Ib/II, MULTICENTER, RANDOMIZED, SINGLE-MASKED, SHAM INJECTION−CONTROLLED STUDY OF SAFETY, TOLERABILITY, AND EVIDENCE OF ACTIVITY OF FCFD4514S INTRAVITREAL INJECTIONS ADMINISTERED MONTHLY OR... | |||||||||||||
Medical condition: Geographic Atrophy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-000578-41 | Sponsor Protocol Number: GX28198 | Start Date*: 2012-12-05 | |||||||||||
Sponsor Name:GENENTECH, Inc. | |||||||||||||
Full Title: A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF LAMPALIZUMAB (FCFD4514S) IN PATIENTS WITH GEOGRAPHIC ATROPHY WHO HAVE COMPLETED GENENTECH-SPONSORED LA... | |||||||||||||
Medical condition: Geographic Atrophy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-022726-33 | Sponsor Protocol Number: 251001 | Start Date*: 2011-03-24 | |||||||||||
Sponsor Name:Baxter Innovations GmbH | |||||||||||||
Full Title: BAX326 (recombinant Factor IX): Evaluation of Safety, Immunogenicity, and Hemostatic Efficacy in Previously Treated Patients with Severe (FIX level < 1%) or Moderately Severe (FIX level 1- 2%) Hemo... | |||||||||||||
Medical condition: Previously treated patients (PTPs) with severe (FIX level < 1%) or moderately severe (FIX level 1- 2%) hemophilia B. | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BG (Completed) CZ (Completed) GB (Completed) DE (Prematurely Ended) SE (Completed) PL (Completed) ES (Completed) IT (Completed) IE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-002571-24 | Sponsor Protocol Number: 15/0118 | Start Date*: 2016-10-14 |
Sponsor Name:Joint Research Office | ||
Full Title: A Phase IIA Prospective, Single-Centre, Open Label Clinical Trial to Evaluate the Safety, Tolerability and Pharmacodynamic Effects of Ambroxol in Patients with Parkinson Disease: Ambroxol in Diseas... | ||
Medical condition: Parkinson disease | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
